Sökning: "DLBCL"
Visar resultat 1 - 5 av 44 avhandlingar innehållade ordet DLBCL.
1. Prognostic Markers in Diffuse Large B-cell Lymphoma : How Bad can it be
Sammanfattning : Diffuse large B-cell lymphoma (DLBCL), which is the most common type of lymphoma, is characterised by its aggressiveness and poor outcome without adequate treatment and also for its biological and clinical heterogeneity. It is therefore highly desirable to gain a more profound understanding of the underlying biology of the disease, as well as predictive factors for the guidance of treatment. LÄS MER
2. Clinical and tumour biology studies of Diffuse Large B-cell Lymphoma : with emphasis on comorbidity, toxicity and outcome
Sammanfattning : Diffuse large B-cell lymphoma (DLBCL) is curable in around 70% when treated with standard immunochemotherapy R- CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). Treatment related toxicity affecting survivors is a clinical problem as well as comorbidities influencing the possibility to give adequate treatment. LÄS MER
3. Potential New Drugs in Lymphoma
Sammanfattning : Lymphomas are malignant tumours arising from cells in the lymphatic system. They are classified as B-cell lymphomas, T-cell lymphomas and Hodgkin lymphoma (HL). Of the B-cell lymphomas, one of the most common is diffuse large B-cell lymphoma (DLBCL). LÄS MER
4. Diffuse large B-cell lymphoma - proteomic and metabolomic studies on prognosis and treatment failure
Sammanfattning : Abstract Background and aim: Every year almost 600 patients in Sweden are diagnosed with diffuse large B-cell lymphoma (DLBCL), the most common lymphoma, and with immunochemotherapy, approximately 60 % are cured. Yet, for patients with primary refractory disease or early relapse, the prognosis is very poor. LÄS MER
5. Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma
Sammanfattning : The general aim of this thesis was to study the prognostic clinical and biological markers of Diffuse Large B-cell Lymphoma (DLBCL).Paper I: Utilizing population-based data for patients with DLBCL in Sweden, the study aimed to establish whether event free survival at 24 months (EFS24) was a reproducible milestone. LÄS MER